患者血栓性微血管病中可溶性血小板糖蛋白 VI (GPVI) 血浆水平升高。
Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy.
机构信息
Departments of Hematology and Oncology, Mie University Hospital and Mie University Graduate School of Medicine, Tsu, Japan.
Biology Laboratory, Discovery Research, Mochida Pharmaceutical CO., LTD. Shizuoka, Japan.
出版信息
Thromb Res. 2014 Mar;133(3):440-4. doi: 10.1016/j.thromres.2013.11.023. Epub 2013 Dec 1.
BACKGROUND
Thrombotic microangiopathy (TMA) is caused by various conditions, such as decreased a ADAMTS13 level, activated or injured vascular endothelial cells or activated platelets. This study examined the soluble platelet glycoprotein VI (sGPVI) levels in patients with TMA to evaluate the activation of platelets in thrombotic states.
MATERIALS AND METHODS
The plasma levels of sGPVI, ADAMTS13 activity, von Willebrand factor (VWF) and VWF propeptide (VWFpp) were measured in patients with TMA.
RESULTS
The plasma levels of sGPVI were significantly higher in postoperative patients, patients with TMA and those with disseminated intravascular coagulation (DIC) than in those without thrombosis. The plasma levels of sGPVI were the highest in patients with TMA without markedly reduced ADAMTS13 and those were significantly reduced after plasma exchange.
CONCLUSION
The measurement of sGPVI level is therefore considered to be important for the diagnosis and evaluation of TMA.
背景
血栓性微血管病（TMA）由多种情况引起，例如 ADAMTS13 水平降低、血管内皮细胞激活或损伤或血小板激活。本研究检测了 TMA 患者的可溶性血小板糖蛋白 VI（sGPVI）水平，以评估血栓形成状态下血小板的激活情况。
材料和方法
测量了 TMA 患者的血浆 sGPVI、ADAMTS13 活性、血管性血友病因子（VWF）和 VWF 前肽（VWFpp）水平。
结果
术后患者、TMA 患者和弥散性血管内凝血（DIC）患者的血浆 sGPVI 水平明显高于无血栓患者。TMA 患者中 sGPVI 水平最高，ADAMTS13 水平无明显降低，且血浆置换后显著降低。
结论
因此，sGPVI 水平的测量被认为对 TMA 的诊断和评估很重要。
Zotero 插件